Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BMEA | US
0.03
2.16%
Healthcare
Biotechnology
30/06/2024
09/03/2026
1.42
1.35
1.50
1.32
Biomea Fusion Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219 an orally bioavailable potent and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion Inc. was incorporated in 2017 and is headquartered in Redwood City California.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
60.1%1 month
61.8%3 months
79.0%6 months
95.2%-
-
3.98
0.10
0.08
-3.75
-
-
-146.72M
51.42M
51.42M
-
-
-
-
-85.09
9.35
35.67
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.26
Range1M
0.30
Range3M
0.63
Rel. volume
1.64
Price X volume
2.01M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| InflaRx N.V | IFRX | Biotechnology | 0.9512 | 56.01M | -1.94% | n/a | 0.00% |
| Minerva Neurosciences Inc | NERV | Biotechnology | 8 | 55.95M | 33.11% | n/a | -194.60% |
| Mawson Infrastructure Group Inc. Common Stock | MIGI | Biotechnology | 2.75 | 51.02M | -1.08% | n/a | 571.64% |
| ImmuCell Corporation | ICCC | Biotechnology | 6.48 | 50.76M | -1.82% | n/a | 67.52% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.6 | 49.56M | 3.23% | n/a | 1.95% |
| Entera Bio Ltd | ENTX | Biotechnology | 1.33 | 48.31M | 6.40% | n/a | 3.91% |
| IMNN | IMNN | Biotechnology | 3.12 | 44.93M | -3.70% | n/a | 37.13% |
| Inovio Pharmaceuticals Inc | INO | Biotechnology | 1.73 | 44.92M | -0.57% | n/a | 13.42% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.49 | 43.71M | 2.52% | n/a | -6472.02% |
| Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 1.08 | 43.34M | 4.85% | n/a | 2.71% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.23 | 32.59M | 0.90% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.75 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.98 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 78.97 | 72.80 | Par |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 51.42M | 3.66B | Emerging |